Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cash & Equivalents (2016 - 2022)

Historic Cash & Equivalents for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $60.7 million.

  • Avadel Pharmaceuticals' Cash & Equivalents rose 437.69% to $60.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $60.7 million, marking a year-over-year increase of 437.69%. This contributed to the annual value of $50.7 million for FY2021, which is 2929.92% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Cash & Equivalents of $60.7 million as of Q3 2022, which was up 437.69% from $54.1 million recorded in Q2 2022.
  • In the past 5 years, Avadel Pharmaceuticals' Cash & Equivalents ranged from a high of $102.2 million in Q2 2020 and a low of $9.3 million during Q4 2018
  • Over the past 5 years, Avadel Pharmaceuticals' median Cash & Equivalents value was $54.1 million (recorded in 2022), while the average stood at $45.9 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 7646.11% in 2019, then soared by 66330.22% in 2020.
  • Quarter analysis of 5 years shows Avadel Pharmaceuticals' Cash & Equivalents stood at $9.3 million in 2018, then grew by 4.82% to $9.8 million in 2019, then surged by 633.8% to $71.7 million in 2020, then decreased by 29.3% to $50.7 million in 2021, then rose by 19.73% to $60.7 million in 2022.
  • Its last three reported values are $60.7 million in Q3 2022, $54.1 million for Q2 2022, and $60.9 million during Q1 2022.